Solid Biosciences (SLDB) Debt Ratio (2024 - 2026)

Solid Biosciences' (SLDB) quarterly Debt Ratio came in at 0.01 in Q1 2026, down 43.24% year-on-year from 0.01 in Q1 2025, and down 79.98% quarter-over-quarter from 0.04 in Q4 2025.

Solid Biosciences (SLDB) Debt Ratio (2024 - 2026) Analysis & Trends

Solid Biosciences has disclosed Debt Ratio across 3 years of filings, most recently posting 0.01 for Q1 2026.

  • Debt Ratio for Q1 2026 came in at 0.01, down 43.24% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01 (down 43.24% YoY), and the FY2025 annual result was 0.04, up 136.95% from the prior year.
  • Debt Ratio came in at 0.01 for Q1 2026 at Solid Biosciences, down from 0.04 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.04 in Q4 2025 to a low of 0.01 in Q1 2026.
  • The 3-year median for Debt Ratio is 0.02 (2024), against an average of 0.02.
  • Across the five-year window, Debt Ratio surged 136.95% in 2025 and plunged 43.24% in 2026, its largest moves.
  • Solid Biosciences' Debt Ratio stood at 0.02 in 2024, then soared by 136.95% to 0.04 in 2025, then tumbled by 79.98% to 0.01 in 2026.
  • The last three Debt Ratio figures came in at 0.01 (Q1 2026), 0.04 (Q4 2025), and 0.02 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn - -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn - -
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn - -
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn 0.18
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn - -
6 Evaxion A 1,522.09 Bn 1,522.07 Bn - -
7 Psyence Biomedical 229.39 Bn 229.38 Bn - -
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn -
9 Abivax 90.15 Bn 90.15 Bn - -
10 Solid Biosciences 789.54 Mn 408.86 Mn - 0.01

Historic Data

Download Data
DateValue
Mar 31, 2026 0.01
Dec 31, 2025 0.04
Sep 30, 2025 0.02
Jun 30, 2025 0.02
Mar 31, 2025 0.01
Dec 31, 2024 0.02
Sep 30, 2024 0.02